While 2023 and into 2024 might have been some of the most challenging times for Marinette’s Dan Buyarski and his health, ...

Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...